News
PRTA
25.16
+1.66%
0.41
CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug
NASDAQ · 1d ago
Weekly Report: what happened at PRTA last week (0318-0322)?
Weekly Report · 3d ago
Labcorp expands Alzheimer's testing portfolio with new diagnostic
Healthcare Labcorp expands Alzheimer's testing portfolio with new diagnostic. The pTau217 test is designed to identify phosphorylated tau 217, a key blood-based biomarker in the disease. Alzheimer's is the most common form of dementia and an estimated 6.7M Americans suffer from the condition.
Seeking Alpha · 03/20 13:00
Weekly Report: what happened at PRTA last week (0311-0315)?
Weekly Report · 03/18 09:16
Demystifying Prothena Corp: Insights From 8 Analyst Reviews
8 analysts have published ratings on Prothena Corp (NASDAQ:PRTA) in the last three months. The biotechnology company focuses on protein dysregulation and a pipeline of investigational therapeutics. The company has an average price target of $72.5 and a 12-month growth rate of -99.37%. The company's revenue growth is lower than its industry peers.
Benzinga · 03/13 14:00
Prothena Price Target Maintained With a $90.00/Share by HC Wainwright & Co.
Dow Jones · 03/13 13:36
Prothena Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/13 13:36
HC Wainwright & Co. Maintains Buy on Prothena Corp, Maintains $90 Price Target
Benzinga · 03/13 13:25
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Belite Bio, Inc. ADR (BLTE) and Prothena (PRTA)
3 analysts have reiterated Buy ratings on Crinetics Pharmaceuticals, Belite Bio, Inc. ADR and Prothena. The 3 stocks are in the Healthcare sector. Belite bio, Inc., has a price target of $59.50. Crinetic Pharmaceuticals has an analyst consensus of Strong Buy with a $54.00 price target.
TipRanks · 03/13 10:20
Weekly Report: what happened at PRTA last week (0304-0308)?
Weekly Report · 03/11 09:16
Piper Sandler Reaffirms Their Buy Rating on Prothena (PRTA)
TipRanks · 03/07 12:36
Prothena to Participate in Upcoming Healthcare Conferences
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation. The company's senior management team will participate in the following upcoming investor conferences. Prothena has a robust pipeline of investigational therapeutics built on protein dys regulation expertise.
Barchart · 03/05 15:05
Weekly Report: what happened at PRTA last week (0226-0301)?
Weekly Report · 03/04 09:16
Weekly Report: what happened at PRTA last week (0219-0223)?
Weekly Report · 02/26 09:18
Prothena: Initial statement of beneficial ownership of securities
Press release · 02/24 00:47
Prothena: Alzheimer's Data Update In 2024 Could Move The Needle
Prothena Corporation plc has an update coming on the phase 1 study using PRX012 for the treatment of patients with Alzheimer's Disease, expected in 2024. The global market for Alzheimer's disease is estimated to reach $15.5 billion by 2031. Prothena is already in the process of exploring the use of PRx012 in the ongoing phase 3 ASCENT-2 study.
Seeking Alpha · 02/23 17:31
Prothena files to offer ordinary shares
Prothena files to offer ordinary shares Feb. 22, 2024. Prothena Corporation plc (PRTA) Stock. Prothena filed a prospectus related to an offering of its ordinary shares without disclosing the amount. The filing is not an offer to sell these securities.
Seeking Alpha · 02/22 22:44
Prothena Appoints Daniel G. Welch as New Board Chair
TipRanks · 02/21 21:28
Prothena appoints Daniel G. Welch as Chair Designate
Healthcare Prothena appoints Daniel G. Welch as Chair Designate. Lars Ekman will step down as Chair and continue to serve on the board as Chair Emeritus. Prothena Corporation plc (PRTA) Stock. Daniel Welch to be appointed as an independent director and chairdesignate.
Seeking Alpha · 02/21 21:22
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
Prothena Corporation plc announced today the appointment of Daniel G. Welch to its Board of Directors as an independent director and Chair Designate. The company is a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise. Mr. Welch will replace Lars Ekman as Chair of the Board.
Barchart · 02/21 15:05
More
Webull provides a variety of real-time PRTA stock news. You can receive the latest news about Prothena through multiple platforms. This information may help you make smarter investment decisions.
About PRTA
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.